MedTrace Logo

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

NCT01178697 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2010-08-10

No results posted yet for this study

Summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

Bevasizumab

Intravitreal, 1.25 mg, 3 times, one month apart.

DRUG

Triamcinolone Acetonide

Intravitreal, 2 mg, 2 times, two months apart.

Sponsors & Collaborators

  • Ophthalmic Research Center

    collaborator AMBIG

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-09-30
Completion
2010-12-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178697 on ClinicalTrials.gov